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ABSTRACT
PU-H71, a heat shock protein 90 (Hsp90) inhibitor, has yielded therapeutic efﬁcacy in many preclinical models
and is currently in clinical trials. Carbon-ion radiotherapy (CIRT) has provided successful tumor control; how-
ever, there is still room for improvement, particularly in terms of tumor-speciﬁc radiosensitization. The Hsp90
inhibitor PU-H71 has been shown to sensitize tumor cells to X-ray radiation. A murine osteosarcoma cell
line (LM8) and a normal human ﬁbroblast cell line (AG01522) were treated with PU-H71 before X-ray, 14- or
50-keV/µm carbon-ion beam (C-ion) irradiation. Cell survival and protein expression were evaluated with col-
ony formation and western blot, respectively. Treatment with PU-H71 alone was shown to be non-toxic to both
cell lines; however, PU-H71 was shown to signiﬁcantly sensitize LM8 cells to not only X-ray, but also to C-ion
irradiation, while only a minimal sensitizing effect was observed in AG01522 cells. PU-H71 treatment was found
to suppress the protein expression levels of Rad51 and Ku70, which are associated with the homologous recom-
bination pathway and the non-homologous end-joining pathway of double-strand break repair. The ﬁndings
reported here suggest that PU-H71 could be a promising radiosensitizer for CIRT.
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INTRODUCTION
Carbon-ion radiotherapy (CIRT) has proved successful in controlling
various kinds of tumors, e.g. prostate cancer, lung cancer and bone/
soft tissue cancer [1]. However, there is still room for improvement
in CIRT, particularly in terms of controlling radioresistant tumors,
with minimal effects on normal tissues. Radiosensitizers function to
further improve radiotherapy by sensitizing tumor cells to radiation,
thereby achieving the same effects with a lower radiation dose.
Although there have been many reports on radiosensitizers for
X-rays, there are few studies on radiosensitizers for carbon-ion
beams (C-ion).
Hsp90 is an attractive target for cancer therapy, since the expres-
sion of Hsp90 is higher in cancer cells than in normal cells, and
compared with normal cells, cancer cells are more dependent on
Hsp90 for survival [2, 3]. Many Hsp90 inhibitors have been devel-
oped and yield good therapeutic efﬁcacy; however, the unfavorable
toxicity of these agents have limited their clinical application. PU-
H71, a novel heat shock protein 90 (Hsp90) inhibitor with an IC50
of 65–140 nM in triple-negative breast cancer cell lines, has been
reported to have anti-tumor effects in many preclinical models
[4, 5]. Two phase I clinical trials in patients with solid tumors or
lymphoma are ongoing, and PU-H71 is now gaining attention as a
novel drug [6, 7]. PU-H71, which is considered the most promising
Hsp90 inhibitor, is a derivative of PU-3 and was designed to have
high solubility as well as speciﬁcity to the ATP-binding regions of
Hsp90. Hsp90 plays its role via a complex cycle regulated by the
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binding and hydrolysis of ATP, and PU-H71 inhibits Hsp90 activity
by blocking ATP binding [2]. Hsp90 inhibition is also an attractive
strategy for combination therapy, and there are several reports of
Hsp90 inhibitors showing effective lethal damage to tumor cells in
combination with X-rays [8–11]. There are only a few studies evalu-
ating the sensitizing effect of Hsp90 inhibitor to high-LET C-ions
[9, 12], and their conclusions are still controversial.
MATERIALS AND METHODS
Cell culture and reagents
The murine osteosarcoma cell line LM8 (target tumor cells) and
the normal human ﬁbroblast cell line AG01522 were kindly pro-
vided by Drs Itoh (Research Institute, Osaka Medical Center for
Cancer and Cardiovascular Diseases) and Hamada (Central
Research Institute of Electric Power Industry), respectively. The
cells were cultured in Eagle’s Minimum Essential Medium (EMEM;
Sigma-Aldrich, Castle Hill, Australia) supplemented with fetal
bovine serum (10% and 18% for LM8 and AG01522 cells, respect-
ively), 100 U/ml penicillin and 100 µg/ml streptomycin. PU-H71
(8-[(6-iodo-1,3-benzodioxol-5-yl)sulfanyl]-9-[3-(propan-2-ylamino)
propyl]purin-6-amine) (Tocris Bioscience, Bristol, UK) was dis-
solved in dimethyl sulfoxide (DMSO), and 0.1 mM stock solutions
of the compound were stored at –30°C. PU-H71 stock (or DMSO
as a control) was added to the culture medium (1/1000 dilution)
24 h prior to irradiation.
Irradiation
C-ion irradiation was achieved by a 290-MeV/nucleon beam at
NIRS-HIMAC. C-ions at either the entrance (14 keV/µm) or the
center (50 keV/µm) of a 6-cm spread-out Bragg-peak (SOBP) were
used to irradiate LM8 cells [13], while AG01522 cells were only
irradiated at the entrance of the SOBP. The dose rate was ~1 Gy/min.
Cells were also irradiated with X-rays produced by a generator
(TITAN-320, GE Healthcare) at a dose rate of ~1 Gy/min.
Colony formation assay
Cell survival curves were obtained from colony formation assay
[14]. Brieﬂy, cells were treated with medium containing 0.1 µM PU-
H71 or 0.1% DMSO for 24 h before irradiation. Irradiated cells
were harvested with 0.02% trypsin, diluted with fresh medium,
counted, and diluted. Cell suspensions expected to yield ~100 sur-
viving cells were seeded onto 6-cm culture dishes in triplicate and
were incubated for 13 (AG01522) or 14 (LM8) days. Colonies con-
taining >50 cells were counted to determine the number of viable
cells.
Western blot analysis
Western blot analysis was carried out as described previously [15].
Brieﬂy, cell lysates were prepared in RIPA buffer (WEG2450,
Wako, Tokyo) containing 4% protease inhibitor (No.11697 498
001, Roche). Lysates (15 µg protein) were loaded into the wells of
an SDS-PAGE gel (AE-6000, ATTO, Tokyo) and run using an
electrophoresis system. The proteins were transferred from the
SDS-PAGE gel onto immunoblot membranes, which were then
incubated with primary antibodies (Rad51 #8875 and Ku70 #4588
from Cell Signaling TECHNOLOGY, Tokyo, and Actin, MAB1501
from Chemicon International, Inc. Billerica) for 1 h at room tem-
perature and then with secondary antibodies (Anti-Rabbit IgG
HRP-linked Antibody#7074 and Anti-Mouse IgG HRP-linked
Antibody#7076, Cell signaling TECHNOLOGY, Tokyo) for 1 h.
The resulting band intensities detected by chemiluminescence were
quantiﬁed using ImageJ 1.46r software.
Statistical analysis
A student’s t-test was performed to analyze differences in data
between PU-H71-treated and untreated samples. Differences with
P < 0.05 were considered statistically signiﬁcant.
RESULTS AND DISCUSSION
The colony formation assay revealed that PU-H71 treatment alone
(0.1 µM) for 24 h had no signiﬁcant cytotoxic effect on AG01522
or LM8 cells (Fig. 1). The radiosensitizing effect of PU-H71 on
LM8 cells was determined by evaluating cell survival after treat-
ment with PU-H71 in combination with X-rays, 14- or 50-keV/µm
C-ions (Fig. 2). Although treatment with PU-H71 alone was not
toxic to LM8 cells, PU-H71 was found to signiﬁcantly sensitize
LM8 cells to not only X-ray but also to C-ion exposure after 24 h
of PU-H71 treatment, and the D10 (dose decreasing the surviving
fraction to 10%) for LM8 shifted from 6.16 ± 0.03, 5.70 ± 0.04
and 4.28 ± 0.08 Gy to 4.80 ± 0.13, 4.01 ± 0.15 and 3.24 ± 0.06 Gy
for X-rays, 14-keV/µm C-ions, and 50-keV/µm C-ions, respectively.
The enhancement ratios at D10 (E.R.10) were thus 1.29 ± 0.04,
1.43 ± 0.05 and 1.32 ± 0.05 for the three radiation types, respect-
ively. It tends to be particularly challenging to sensitize tumors to
high-LET radiation such as C-ion with other treatments, including
anti-cancer drugs, because of the strong cell-killing effect of the C-
ion itself. Such sensitization is, furthermore, made challenging by
the fact that the efﬁcacy of the combination therapy has to not only
be superior to the efﬁcacies of each single therapy, but the side
Fig. 1. PU-H71 (0.1 µM) cytotoxicity in murine osteosar-
coma (LM8) and human normal ﬁbroblast (AG01522) cells.
Data represent mean ± standard error (SE); n = 4–5; *P <
0.05 compared with PU(–).
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effects of the combination therapy have to be less signiﬁcant than
the sum of those of each single treatment. Effective combination
therapy doses must, therefore, be lower than the doses used with
each single therapy [16]. PU-H71 was shown to sensitize LM8 cells
with a drug concentration that does not affect cell survival itself,
suggesting that PU-H71 has high potential as a radiosensitizer for
CIRT.
In radiotherapy, the protection of normal tissue is an important
factor to consider in addition to improvement of the therapeutic
outcome. To assess the safety of PU-H71/radiation combination
therapies in normal tissues, the PU-H71/radiation therapies were
assessed in normal AG01522 cells (Fig. 3). In the AG01522 cells,
no signiﬁcant sensitizing effect was observed with X-rays. In the
case of 14-keV/µm C-ions, the D10 value for AG01522 cells shifted
from 3.10 ± 0.04 Gy to 2.77 ± 0.11 Gy; however, the radiosensitiz-
ing effect was extremely weak (E.R.10 = 1.12 ± 0.05). These ﬁnd-
ings suggest that PU-H71 treatment may provide signiﬁcant
radiosensitizing effects in LM8 cancer cells with minimal damage to
normal (AG01522) cells.
The lethal effect of radiation on cells is primarily caused by
DNA double-strand breaks (DSBs) [16]; and many DSB-associated
proteins are Hsp90 client proteins. In this study, therefore, DSB
repair–associated proteins were the focus of the protein expression
analysis: the protein expression levels of Rad51 and Ku70, proteins
involved in the two major DSB repair pathways (homologous
recombination and non-homologous end joining, respectively
[17, 18], were measured. Rad51 expression in LM8 cells was
reduced by treatment with PU-H71 alone: expression in untreated
Fig. 2. Radiosensitivity of murine osteosarcoma (LM8) cells exposed to X-rays, 14- and 50-keV/µm C-ions combined
with/without PU-H71 treatment. Data represent mean ± SE; n = 3; (P > 0.00029, 0.00022 and 0.00025 for the three
radiation types at D10, respectively).
Fig. 3. Radiosensitivity of human normal ﬁbroblast cells
(AG01522) exposed to X-ray or 14-keV/µm C-ion radiation
with (triangles) or without (circles) PU-H71 pretreatment.
Data represent mean ± SE; n = 3; (P > 0.38 and 0.025 for
the two radiation types at D10, respectively).
Fig. 4. Expression levels of proteins associated with DNA
double-strand breaks in LM8 cells after irradiation with or
without PU-H71 pretreatment. The ratios of the band inten-
sities of each protein relative to actin are indicated below
the images.
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cells peaked at 1–3 h post irradiation before decreasing gradually over
time; while in PU-H71-treated cells, Rad51 expression remained
unchanged by 1 h post-irradiation and then gradually increased, but
still remained lower than the levels in untreated cells at the corre-
sponding time points. The expression of Ku70 after C-ion irradiation
was also shown to be suppressed by PU-H71 treatment and showed
similar changes with radiation; however, the suppressive effect on
Ku70 expression was less marked than that on Rad51 expression
(Fig. 4). Inhibition of Rad51 is reportedly a mechanism of X-ray
radiosensitizing by PU-H71 [8]. In this study, this was also demon-
strated for C-ion radiosensitizing. Although further studies are needed
to fully understand the mechanism of the radiosensitizing effect of
PU-H71, our results suggest that the radiosensitizing effect of PU-
H71 on C-ions could also be associated with the inhibition of the
non-homologous end-joining DSB repair pathway.
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